Integral Health Asset Management LLC Purchases New Shares in Humana Inc. (NYSE:HUM)

Integral Health Asset Management LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 40,000 shares of the insurance provider’s stock, valued at approximately $10,148,000.

Several other hedge funds also recently made changes to their positions in HUM. Jacobs Levy Equity Management Inc. raised its stake in Humana by 0.3% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 589,287 shares of the insurance provider’s stock valued at $149,508,000 after buying an additional 1,615 shares during the last quarter. Humankind Investments LLC increased its holdings in shares of Humana by 32.6% during the fourth quarter. Humankind Investments LLC now owns 1,612 shares of the insurance provider’s stock valued at $409,000 after acquiring an additional 396 shares in the last quarter. Gotham Asset Management LLC increased its holdings in shares of Humana by 38.9% during the fourth quarter. Gotham Asset Management LLC now owns 32,593 shares of the insurance provider’s stock valued at $8,269,000 after acquiring an additional 9,132 shares in the last quarter. Ethic Inc. increased its holdings in shares of Humana by 7.7% during the fourth quarter. Ethic Inc. now owns 8,641 shares of the insurance provider’s stock valued at $2,192,000 after acquiring an additional 619 shares in the last quarter. Finally, Fred Alger Management LLC bought a new position in shares of Humana during the fourth quarter valued at $451,000. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Performance

NYSE HUM opened at $249.67 on Monday. The stock’s fifty day moving average is $265.21 and its two-hundred day moving average is $270.47. The firm has a market capitalization of $30.13 billion, a P/E ratio of 25.09, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $7.23 earnings per share. On average, research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.42%. The ex-dividend date is Friday, June 27th. Humana’s dividend payout ratio (DPR) is presently 25.04%.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HUM shares. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 price target on shares of Humana in a report on Thursday, May 1st. StockNews.com upgraded Humana from a “hold” rating to a “buy” rating in a report on Friday. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price objective for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $283.00 price objective on shares of Humana in a report on Wednesday, February 12th. Finally, Morgan Stanley reduced their price objective on Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. Seventeen equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $287.76.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.